WET AMD
Wet age-related macular degeneration (wet AMD) is driven by choroidal neovascularization and vascular leakage, making it a critical target for anti-angiogenic and gene-based therapies.
However, preclinical wet AMD models present significant translational challenges, including species-specific anatomy (e.g., absence of a true macula in most animals) and incomplete replication of human disease progression.
Successful translation requires careful model selection, multi-species validation, and alignment of pharmacologic mechanisms with disease biology to generate predictive, clinically relevant efficacy data.
​
DL-AAA Induced Retinal Neovascularization
The DL-2-aminoadipic acid (AAA) model of chronic retinal neovascularization is used to evaluate the durability of test articles targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy through quantification of vascular leakage inhibition. Our team of experts has developed this model with consistent results in the Dutch Belted rabbit.
Laser-Induced Choroidal Neovascularization
The experimental laser-induced CNV model is used to evaluate the efficacy of test articles targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Our team of experts has developed reproducible models with consistent results in mice, rats, and swine.
VEGF- Induced Retinal Leakage and Neovascularization
The VEGF-induced retinal leakage model is used to assess the efficacy of test articles targeting wet age-related macular degeneration (wet AMD) and diabetic retinopathy. Our team of experts has developed this model with consistent results in the Dutch Belted rabbit.